(1 - 9 from 14
)
Amunix Announces Licensing Agreement with Merck for ...www.globalbankingandfinance.com › category › news › amunix-ann...
www.globalbankingandfinance.com
... said Rob Kastelein, Ph.D., Associate Vice President, Immune-Oncology Discovery, Merck Research Laboratories. We look forward to working ...
Press Release | Amunix …s
www.amunix.com
Jan 3, · ... development programs,” said Rob Kastelein, Ph.D., Associate Vice President, Immune-Oncology Discovery, Merck Research Laboratories.
Complix Launches Strategic Collaboration with Merck ...www.technologynetworks.com › drug-discovery › news › complix-laun...
www.technologynetworks.com
... immuno-oncology clinical development program,” said Dr. Rob Kastelein, scientific associate vice president, MSD Research Laboratories.
Policy and Regulations - M2 Pharmawww.m2pharma.com › news › policy-and-regulations › article
www.m2pharma.com
... development programmes, said Rob Kastelein, PhD, Associate Vice President, Immune-Oncology Discovery, Merck Research Laboratories.
sorted by relevance / date